(2R,3R,4S,5R)-2-(6-(benzyloxy)-9H-purin-9-yl)-5-(hydroxymethyl)-tetrahydrofuran-3,4-diol

ID: ALA259868

Chembl Id: CHEMBL259868

PubChem CID: 44451142

Max Phase: Preclinical

Molecular Formula: C17H18N4O5

Molecular Weight: 358.35

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  OC[C@H]1O[C@@H](n2cnc3c(OCc4ccccc4)ncnc32)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C17H18N4O5/c22-6-11-13(23)14(24)17(26-11)21-9-20-12-15(21)18-8-19-16(12)25-7-10-4-2-1-3-5-10/h1-5,8-9,11,13-14,17,22-24H,6-7H2/t11-,13-,14-,17-/m1/s1

Standard InChI Key:  YKCFRYNFIUFWOG-LSCFUAHRSA-N

Associated Targets(Human)

SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1711 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RD (1212 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
STING1 Tchem Stimulator of interferon genes protein (1885 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Enterovirus A71 (1246 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 358.35Molecular Weight (Monoisotopic): 358.1277AlogP: 0.02#Rotatable Bonds: 5
Polar Surface Area: 122.75Molecular Species: NEUTRALHBA: 9HBD: 3
#RO5 Violations: 0HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.45CX Basic pKa: 2.48CX LogP: 0.30CX LogD: 0.30
Aromatic Rings: 3Heavy Atoms: 26QED Weighted: 0.58Np Likeness Score: 0.56

References

1. Zhu Z, Buolamwini JK..  (2008)  Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity.,  16  (7): [PMID:18289860] [10.1016/j.bmc.2008.01.044]
2. Drenichev MS, Oslovsky VE, Sun L, Tijsma A, Kurochkin NN, Tararov VI, Chizhov AO, Neyts J, Pannecouque C, Leyssen P, Mikhailov SN..  (2016)  Modification of the length and structure of the linker of N(6)-benzyladenosine modulates its selective antiviral activity against enterovirus 71.,  111  [PMID:26854380] [10.1016/j.ejmech.2016.01.036]
3. Bonnac LF, Dreis CD, Geraghty RJ..  (2020)  Structure activity relationship, 6-modified purine riboside analogues to activate hSTING, stimulator of interferon genes.,  30  (2): [PMID:31780305] [10.1016/j.bmcl.2019.126819]

Source